Saturday 17 October 2026
Export ELAB’s income statement to Excel — free account
PMGC Holdings Inc.
ELAB Healthcare Biotechnology
PMGC Holdings Inc.’s revenue for fiscal 2025 (year ended December 2025) was $590,100.00, down 65.5% from fiscal 2023. In the quarter to June 2026, revenue grew 147.7%, EPS grew 98.4% and free cash flow fell 45.0%, each against the same quarter a year earlier.
2.77
0.27
−8.88%
Follow ELAB
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(78.61%) | (106.89%) | (107.14%) | (104.60%) | |
| (51.26%) | (70.88%) | (63.61%) | (58.71%) | ||
ROIC |
0.00% | (220.80%) | 0.00% | 0.00% | |
Return on Tangible Assets |
(141.82%) | (203.12%) | (162.38%) | (182.09%) | |
Average Days of Receivables |
66.30 | 72.13 | 110.08 | 85.43 | |
Free Cash Flow per Share |
(2,993.68) | (3,191.10) | (188.12) | (18.44) | |
Free Cash Flow |
(6.59) | (6.38) | (8.37) | (8.99) | |
Capital Expenditures |
(0.40) | (0.45) | (0.81) | (0.78) | |
| Other line items | |||||
Cash ROIC |
(38.75%) | (45.93%) | (29.84%) | (25.11%) | |
Accounts Receivable Turnover |
10.24 | 9.97 | 6.05 | 7.59 | |
Accounts Payable Turnover |
0.76 | 1.20 | 1.90 | 2.30 | |
Inventory Turnover |
2.17 | 1.35 | 1.61 | 1.85 | |
Average Days of Payables |
298.76 | 361.32 | 242.25 | 261.26 | |
Days of Inventory on Hand |
69.31 | 49.26 | 93.51 | 191.52 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
8.71% | 8.53% | 8.99% | 15.71% | |
Selling, General and Administrative Expense of Revenue |
103.21% | 141.59% | 200.67% | 187.68% | |
Share Based Compensation of Revenue |
0.49% | (1.11%) | 2.66% | 8.01% | |
Interest Coverage |
(77.66) | (26.71) | (12.49) | (9.07) | |
Operating CF/Net income |
0.92 | 0.77 | 0.68 | 0.61 | |
Depreciation/Fixed assets |
0.10 | 0.11 | 0.15 | 0.30 | |
Capex/Depreciation |
(9.99) | (4.64) | (2.99) | (1.36) | |
Revenue per Share |
924.32 | 861.50 | 40.44 | 5.29 | |
Operating CF per Share |
(2,811.14) | (2,966.95) | (170.02) | (16.83) | |
Capex per Share |
(182.55) | (224.15) | (18.10) | (1.61) | |
Capex to Sales |
0.20 | 0.26 | 0.45 | 0.30 |
Columns are period end dates